Oligonucleotide CDMO Market Set to Surge to $6.73B by 2029 at 21.8% CAGR

Bachem is one of key players and well-established companies operating in the Oligo CDMO market. The company is mainly focused on commercial manufacturing of oligonucleotide API and is expected to grow in the oligonucleotide contract manufacturing market.
The report "Oligonucleotide CDMO Market [https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-cdmo-market-227700087.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=oligonucleotidecdmomarket] by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029 ", is projected to reach USD 6.73 billion in 2029 from USD 2.51 billion in 2024, with a CAGR of 21.8%. Factors such as the growing focus on the development and commercialization of oligo-based therapeutics, increasing outsourcing of development and manufacturing to CDMOs, and an increasing focus on a personalized approach to medicine. However, factors such as the high volume of organic & aqueous waste generation and regulatory mandates are posing a challenge to the market growth. Emerging economies are increasingly offering growth opportunities for oligo-CDMO market players.

The therapeutic application subsegment accounted for the largest share of the oligonucleotide CDMO market's application segment in 2023

Based on applications, the oligonucleotide CDMO market is segmented into therapeutic, diagnostic, and research applications. The therapeutic application segment accounted for the largest share of the oligonucleotide CDMO market by application in 2023. Oligonucleotide-based therapies are being developed for a broad spectrum of indications. Moreover, oligonucleotide therapies are one of the key drug classes for precision medicine, targeting specific genetic mutations in individual patients. The increasing adoption of personalized treatments is further enhancing the demand for therapeutic oligonucleotide manufacturing.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=227700087 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=227700087&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=oligonucleotidecdmomarket]

The commercial segment accounted for the largest share of the contract manufacturing market, by stage, during the forecast period.

Based on stage, the oligonucleotide contract manufacturing market is divided into clinical scale and commercial scale. The large share of the commercial segment can be attributed to the fact that commercial manufacturing is an ongoing process throughout the lifecycle of a drug, often spanning years or decades. Thus, commercial-scale production involves sustained and repeated manufacturing, driving higher revenue. With a growing number of oligonucleotide-based therapies receiving regulatory approvals, the need for large-scale production to meet market demand has surged. Recent approvals in fields like oncology, neurology, and infectious diseases have expanded the market for commercial manufacturing services. CDMOs offer capabilities such as advanced facilities, regulatory expertise, and the capacity to handle large-scale production.

Asia Pacific was registered as the fastest-growing region of the Oligonucleotide CDMO market in 2023.

The oligonucleotide CDMO market is divided into six regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America held the largest share of the oligonucleotide CDMO market, followed by Europe. The presence of key market players in the region is a key driving factor. Asia Pacific region is expected to be the fastest growing region during the forecast period owing to factors such as increasing investments by key global players in the region, domestic players enhancing their life sciences infrastructure, and government policies incentivizing R&D are supporting the market growth in the region.

Key players in the oligonucleotide CDMO market include Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Agilent Technologies, Inc. (US), Kaneka Eurogentec S.A. (Belgium), Ajinomoto Co., Inc. (Japan), Aurigene Pharmaceutical Services Ltd. (India), Bachem (Switzerland), Syngene International Limited (India), PolyPeptide Group (Switzerland), WuXi AppTec (China), EUROAPI (France), Eurofins Scientific (Luxembourg), GenScript (US), and Danaher Corporation (US), among others.

Bachem is one of key players and well-established companies operating in the Oligo CDMO market. The company is mainly focused on commercial manufacturing of oligonucleotide API and is expected to grow in the oligonucleotide contract manufacturing market. The company focuses on oligonucleotides and peptides molecules. This makes the company a specialized CDMO in oligonucleotide manufacturing. Bachem collaborates with major pharma biotech companies focusing on oligonucleotide and peptide-based therapeutics development to maintain and enhance its position in the market. The company's manufacturing capabilities, technologically advanced facilities, and regulatory compliance attract end users. For example, in April 2022, Bachem and Lilly signed a collaboration to develop and manufacture oligonucleotide-based drug substances.

Agilent Technologies, Inc. is one of the key players operating in the oligonucleotide Contract Development and Manufacturing Organization (CDMO) market. Agilent offers a wide range of CDMO services for oligonucleotides, such as custom oligonucleotide synthesis, process development and optimization, analytical method development and validation, and large-scale manufacturing for clinical and commercial applications. The company's comprehensive service portfolio, manufacturing capabilities, strong brand recognition and geographic presence are some of the key factors for its strong strategic position in the market.

Thermo Fisher Scientific Inc. is one of the top key players operating in the oligonucleotide Contract Development and Manufacturing Organization (CDMO) market, leveraging its advanced capabilities in scalable oligonucleotide synthesis and end-to-end manufacturing solutions. Its integration of solid-phase synthesis, proprietary purification technologies, and automated high-throughput systems ensures production consistency for therapeutic oligonucleotides such as siRNAs, and ASOs, among others. Thermo Fisher Scientific leads the oligonucleotide CDMO market through its comprehensive service portfolio and robust technological infrastructure. The company's OligoPerfect Primer Designer platform enables customized oligonucleotide design, accelerating development timelines for antisense oligonucleotides (ASOs) and siRNA therapeutics. Additionally, its deep expertise in analytical development, including advanced HPLC, LC-MS, and CE technologies, ensures precise characterization and stringent quality control of oligonucleotides at every production stage. Additionally, the company's strong geographic reach allows it to maintain its position in the market.

For more information, Inquire Now! [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=227700087&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=oligonucleotidecdmomarket]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oligonucleotide-cdmo-market-set-to-surge-to-673b-by-2029-at-218-cagr]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-cdmo-market-227700087.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.